February 15, 2018 / 5:11 PM / 6 days ago

BRIEF-Agios says FDA Accepts NDA And Grants Priority Review For Ivosidenib

Feb 15 (Reuters) - Agios Pharmaceuticals Inc:

* FDA ACCEPTS NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW FOR IVOSIDENIB IN RELAPSED OR REFRACTORY AML WITH AN IDH1 MUTATION

* FDA ACCEPTS NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW FOR IVOSIDENIB IN RELAPSED OR REFRACTORY AML WITH AN IDH1 MUTATION

* AGIOS PHARMACEUTICALS INC - ‍PDUFA DATE SET FOR AUGUST 21, 2018​

* AGIOS PHARMACEUTICALS - ABBOTT SUBMITTED PREMARKET APPROVAL APPLICATION FOR FDA REVIEW OF AN IDH1 ASSAY ON ABBOTT M2000 REALTIME SYSTEM​

* AGIOS PHARMACEUTICALS INC - ‍ABBOTT ASSAY WILL SERVE AS A COMPANION DIAGNOSTIC FOR IVOSIDENIB​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below